NYSEHealth CareMedical DevicesSnapshot 2026-07-23
Reading BFLY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
BFLY represents a speculative growth investment with a focus on achieving significant revenue growth. The current thesis state is intact, as recent performance remains strong relative to industry peers despite ongoing losses.
The market seems to price in a premium compared to peers, reflecting expectations of future growth. However, this premium appears unjustified given the company's current loss-making status and elevated risk factors.
Management is on track to achieve its revenue growth target of 20% to 24% for 2026, but the adjusted EBITDA loss guidance indicates mixed progress on cost control. Gross profit margins are improving, but this remains a key area of focus.
The long-term thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT. If these companies continue to perform well, it could support BFLY's growth, but any negative guidance from them could pose risks.
Over the next 1 to 3 years, BFLY's performance will depend on its ability to navigate sector dynamics and manage operational challenges. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. On one hand, there is confidence in achieving revenue growth of 20% to 24% in 2026, which supports the company's outlook. On the other hand, there are concerns about maintaining adjusted EBITDA loss guidance for 2026, posing risks to financial expectations.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This growth rate confirms management's goal for 2026. It shows strong demand for Butterfly's products.
Confirms:Q2 revenue growth is 20% or more compared to Q2 2025.
Disproves:Q2 revenue growth is below 20% compared to Q2 2025.
Why it matters: This report will provide insights into revenue growth and cost management progress.
Confirms one read:Earnings report shows revenue growth and improved gross profit margins.
Confirms the other:The earnings report shows a drop in revenue or bigger losses.
Why it matters: Meeting or exceeding this guidance shows Butterfly's growth momentum is on track. It confirms management's commitment to achieving 20% to 24% growth for the year.
Confirms:Q2 revenue reported at $27 million or higher.
Disproves:Q2 revenue reported below $27 million.
Why it matters: If revenue growth speeds up, it could help Butterfly Network's performance. It shows the sector is improving.
Confirms:Sector revenue growth speeds up again, reaching over 10%.
Disproves:Sector revenue growth keeps slowing down or stays under 10%.
Why it matters: Better margins mean Butterfly is managing costs and pricing better. This helps Butterfly grow long-term.
Confirms:Gross profit margin improves compared to Q1 2026.
Disproves:Gross profit margin declines compared to Q1 2026.
Why it matters: Staying in this range shows good cost control. It shows management is working to cut losses.
Confirms:Adjusted EBITDA loss reported at $6 million or less.
Disproves:The adjusted EBITDA loss is more than $8 million.
Why it matters: Securing this agreement would validate Butterfly's strategy to expand its market presence. It is a key step in their growth plan.
Confirms:A signed deal for Home & Community Care was announced.
Disproves:No progress or delays were reported in getting the deal.
